Journal Article•
Antioxidant Activities of Decursinol Angelate and Decursin from Angelica gigas Roots
01 Jan 2003-Natural product sciences (The Korean Society of Pharmacognosy)-Vol. 9, Iss: 3, pp 170-173
TL;DR: The anti-oxidant activities of decursinol angelate (1) and Decursin (2) isolated from Angelica gigas were investigated in rats as discussed by the authors, where two coumarins exhibited decrease in serum transaminase activities elevated by hepatic damage induced by in rats.
Abstract: The anti-oxidant activities of decursinol angelate (1) and decursin (2) isolated from Angelica gigas were investigated These two coumarins exhibited decrease in serum transaminase activities elevated by hepatic damage induced by in rats They also showed increase in anti-oxidant enzyme such as hepatic cytosolic superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-px) in rats These results suggest that decursinol angelate (1) and decursin (2) from A gigas possess not only the anti-oxidant, but also the hepatoprotective activities in rats
Citations
More filters
Journal Article•
TL;DR: The novel anticancer efficacy of decursin mediated via induction of cell cycle arrest and apoptosis selectively in human prostate carcinoma cells is suggested.
Abstract: We isolated a coumarin compound decursin (C(19)H(20)O(5); molecular weight 328) from Korean angelica (Angelica gigas) root and characterized it by spectroscopy. Here, for the first time, we observed that decursin (25-100 micromol/L) treatment for 24 to 96 hours strongly inhibits growth and induces death in human prostate carcinoma DU145, PC-3, and LNCaP cells. Furthermore, we observed that decursinol [where (CH(3))(2)-C=CH-COO- side chain of decursin is substituted with -OH] has much lower effects compared with decursin, suggesting a possible structure-activity relationship. Decursin-induced growth inhibition was associated with a strong G(1) arrest (P < 0.001) in DU145 and LNCaP cells, and G(1), S as well as G(2)-M arrests depending upon doses and treatment times in PC-3 cells. Comparatively, decursin was nontoxic to human prostate epithelial PWR-1E cells and showed only moderate growth inhibition and G(1) arrest. Consistent with G(1) arrest in DU145 cells, decursin strongly increased protein levels of Cip1/p21 but showed a moderate increase in Kip1/p27 with a decrease in cyclin-dependent kinases (CDK); CDK2, CDK4, CDK6, and cyclin D1, and inhibited CDK2, CDK4, CDK6, cyclin D1, and cyclin E kinase activity, and increased binding of CDK inhibitor (CDKI) with CDK. Decursin-caused cell death was associated with an increase in apoptosis (P < 0.05-0.001) and cleaved caspase-9, caspase-3, and poly(ADP-ribose) polymerase; however, pretreatment with all-caspases inhibitor (z-VAD-fmk) only partially reversed decursin-induced apoptosis, suggesting the involvement of both caspase-dependent and caspase-independent pathways. These findings suggest the novel anticancer efficacy of decursin mediated via induction of cell cycle arrest and apoptosis selectively in human prostate carcinoma cells.
178 citations
TL;DR: The AGN extract possessed significant in vivo anti-cancer activity, but decursin and DA only contributed moderately to that activity, most likely through decurs inol.
Abstract: We have reported that a 10-herbal traditional formula containing Korean Angelica gigas Nakai (AGN) exerts potent anti-cancer efficacy and identified decursin and decursinol angelate (DA) from AGN as novel anti-androgens. Here, we determined whether AGN would exert in vivo anti-cancer activity and whether decursin or DA could account for its efficacy. The AGN ethanol extract was tested against the growth of mouse Lewis lung cancer (LLC) allograft in syngenic mice or human PC-3 and DU145 prostate cancer xenograft in immunodeficient mice. The pharmacokinetics of decursin and DA were determined. The AGN extract significantly inhibited LLC allograft growth (30 mg/kg) and PC-3 and DU145 xenograft growth (100 mg/kg) without affecting the body weight of the host mice. Biomarker analyses revealed decreased cell proliferation (Ki67, PCNA), decreased angiogenesis (VEGF, microvessel density) and increased apoptosis (TUNEL, cPARP) in treated tumors. Decursin and DA injected intraperitoneally were rapidly hydrolyzed to decursinol. Decursinol and decursin at 50 mg/kg inhibited LLC allograft growth to the same extent, comparable to 30 mg AGN/kg. Therefore the AGN extract possessed significant in vivo anti-cancer activity, but decursin and DA only contributed moderately to that activity, most likely through decursinol.
69 citations
Cites background or result from "Antioxidant Activities of Decursino..."
..., 1997) in vitro as well as their in vivo inhibitory activity against sarcoma (Lee et al., 2003), these compounds could be the putative active agents for...
[...]
...p injection for 9 consecutive days at 50 and 100 mg/kg, caused a significant increase in the life span of acites-bearing mice and a significant decrease in the tumor volume and final tumor weight of mice with subcutaneously-inoculated tumor cells (Lee et al., 2003)....
[...]
...…exerted a modest in vivo anti-cancer activity The pharmacokinetic data suggest the in vivo hydrolysis product decursinol, rather than the parent compounds, will likely mediate the in vivo anti-cancer activity of decursin and DA as reported previously in the sarcoma model (Lee et al., 2003)....
[...]
...Only one article has been published showing decursin and DA to be active in vivo against Sarcoma-180 growth (Lee et al., 2003)....
[...]
...The pharmacokinetic data suggest the in vivo hydrolysis product decursinol, rather than the parent compounds, will likely mediate the in vivo anti-cancer activity of decursin and DA as reported previously in the sarcoma model (Lee et al., 2003)....
[...]
TL;DR: Several natural coumarins isolated from Ferulago campestris and several synthetic ester derivatives of aegelinol were tested against four tumor cell lines and some were shown to be marginally cytotoxic against the A549 lung cancer cell line.
Abstract: Grandivittin (1), agasyllin (2), aegelinol benzoate (3) and felamidin (20), four natural coumarins isolated from Ferulago campestris, and several synthetic ester derivatives of aegelinol (4) were t...
69 citations
Cites background from "Antioxidant Activities of Decursino..."
...Moreover, they possess anti-oxidant and hepatoprotective properties in rats [13], as well as antitumor [14,15] and antibacterial [16] activities....
[...]
TL;DR: The results demonstrate that (1)H NMR and UPLC-MS-based metabolic profiling coupled with chemometric analysis can be used to discriminate the geographical origins of various herbal medicines and to identify primary and secondary metabolites responsible for discrimination.
Abstract: Angelica gigas obtained from different geographical regions was characterized using 1H nuclear magnetic resonance (NMR) spectroscopy and ultraperformance liquid chromatography–mass spectrometry (UPLC-MS) followed by multivariate data analyses. Principal component analysis (PCA) and orthogonal partial least-squares-discriminant analysis (OPLS-DA) score plots from 1H NMR and UPLC-MS data sets showed a clear distinction among A. gigas from three different regions in Korea. The major metabolites that contributed to the discrimination factor were primary metabolites including acetate, choline, citrate, 1,3-dimethylurate, fumarate, glucose, histamine, lactose, malate, N-acetylglutamate, succinate, and valine and secondary metabolites including decursin, decursinol, nodakenin, marmesin, 7-hydroxy-6-(2R-hydroxy-3-methylbut-3-ethyl)coumarin in A. gigas roots. The results demonstrate that 1H NMR and UPLC-MS-based metabolic profiling coupled with chemometric analysis can be used to discriminate the geographical orig...
62 citations
TL;DR: Decursin treatment resulted in the inhibition of adipocyte differentiation and the expression of fatty acid synthase, suggesting that decursin might be useful for the treatment of obesity and diabetes.
Abstract: Decursin (De), an active component of Angelica gigas, is known to exert anticancer and neuroprotective effects. However, its antiobesity and antidiabetic potential has not yet been investigated. This study evaluated the antiobesity effect of decursin, particularly focusing on its ability to inhibit adipocyte differentiation in 3T3-L1 cells. Decursin treatment resulted in the inhibition of adipocyte differentiation and the expression of fatty acid synthase. The study further investigated these antiobesity effects using mice fed a normal diet (ND), a high-fat diet (HFD) and a HFD plus decursin 200 mg/kg diet (HFD + De) for 7 weeks. Mice administered HFD plus decursin showed a drastic decrease in weight gain, triglyceride content, total cholesterol content and fat size compared with those that received the HFD alone; this was observed despite similar quantities of total food intake. Furthermore, decursin improved glucose tolerance in mice fed a HFD. Finally, administration of decursin along with the HFD significantly reduced the secretion of HFD-induced adipocytokines such as leptin, resistin, IL-6 and MCP-1. These results suggest that decursin might be useful for the treatment of obesity and diabetes.
39 citations